BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 20725763)

  • 1. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
    Mégnin-Chanet F; Bollet MA; Hall J
    Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy.
    Li M; Yu X
    Oncogene; 2015 Jun; 34(26):3349-56. PubMed ID: 25220415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
    He JX; Yang CH; Miao ZH
    Acta Pharmacol Sin; 2010 Sep; 31(9):1172-80. PubMed ID: 20676117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
    Pernin V; Mégnin-Chanet F; Pennaneach V; Fourquet A; Kirova Y; Hall J
    Cancer Radiother; 2014 Dec; 18(8):790-8; quiz 799-802. PubMed ID: 25441760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitor development for systemic cancer targeting.
    Zaremba T; Curtin NJ
    Anticancer Agents Med Chem; 2007 Sep; 7(5):515-23. PubMed ID: 17896912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
    Curtin NJ; Szabo C
    Mol Aspects Med; 2013 Dec; 34(6):1217-56. PubMed ID: 23370117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly (ADP-ribose) polymerase inhibitors in cancer treatment.
    Mason KA; Raju U; Buchholz TA; Wang L; Milas ZL; Milas L
    Am J Clin Oncol; 2014 Feb; 37(1):90-100. PubMed ID: 22495455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
    de la Lastra CA; Villegas I; Sánchez-Fidalgo S
    Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of PARP inhibitors in oncology.
    Rodon J; Iniesta MD; Papadopoulos K
    Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase inhibition: past, present and future.
    Curtin NJ; Szabo C
    Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.
    Park SR; Chen A
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):649-70, ix. PubMed ID: 22520984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
    Peralta-Leal A; Rodríguez MI; Oliver FJ
    Clin Transl Oncol; 2008 Jun; 10(6):318-23. PubMed ID: 18558578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.